Articles

Whole Blood or PBMCs for immune profiling?

Jolien Sweere, PhD May 10, 2023

About the Webinar

In this technical webinar, Jolien Sweere, PhD, discusses data from a technical validation experiment performed by Teiko Bio showing how mass cytometry immune profiling data from whole blood compares to data from PBMCs.

Technical validation slides available here.

About the Speaker

Jolien Sweere, PhD completed her doctoral training in Immunology at Stanford University in the laboratory of Paul Bollyky. During her PhD, she found that a type of temperate filamentous bacteriophage that infects Pseudomonas aeruginosa is associated with chronic human wound infections. Her work was published in Science in 2019.

After completing her PhD, Jolien worked as a Life Sciences commercial strategy consultant at Charles River Associates in San Francisco. She joined Teiko Bio in 2022 as a Senior Scientist, Medical Strategy.

Illustration. In the center is a grey mass labeled "tumor" under a magnifying glass. Inside the tumor are three grey cells all with "zzz" above them. Outside the magnifying glass (and therefore outside the tumor) in the four corners are different depictions. Top left shows three red cells and is labeled "novel T cell clones". Top right shows a lymph node with red T cell zones and the words "LN trafficking required". Bottom right shows two red T cells in a blood vessel labeled "LAG-3 and CD8+" with the words "peripheral biomarkers". Bottom left shows a spleen with the same grey, sleeping T cells. There's a red lightning bolt and the words "impaired systemic immune response in cancer".

Peripheral blood analysis is key to developing effective cancer immunotherapies

Although most research focuses on tumor-killing immune cells at the site of the tumor, new research increasingly demonstrates the value of studying circulating immune cells in peripheral blood to identify new therapeutic targets to enhance tumor-killing immune responses. We highlight recent publications with peripheral blood biomarkers and discuss recommendations for how to incorporate peripheral blood immune profiling into your drug development pipeline.

Five things to look for in an immune profiling partner

Make the most of your time and resources by choosing an immune profiling partner who can advance your oncology, autoimmune, or infectious disease pipelines. Here are five things to look for when evaluating an immune profiling partner.

A ring of grey and black in the center split into 3 sections with the words Flow, Mass, Spectral going around it clockwise. A dashed line coming out from the ring separates the rest of the space into three sections. Surrounding the ring are six colored circles each with a white icon. The circles directly opposite each other are the same color, but different shades (red opposite pink, blue opposite light blue, green opposite light green). Red shows a pencil, pink shows a grid-like matrix, Blue shows four dials, light blue shows only two; green shows a heavy metal spectrum with distinct lines, light green shows fluorescence spectrum with overlap. The green circle is in the Mass segment, the red overlaps between Mass and Flow, the Blue overlaps between Mass and Spectral. The Mass segment is the only one without any light colored circles.

Flow vs. Spectral vs. Mass Cytometry: What’s the difference?

What’s the difference between flow, spectral, and mass cytometry? We highlight the differences between these three different cytometry platforms used by drug developers to characterize the immune system so you can determine which platform provides you the richest information to advance your research and therapeutic development.

About the Webinar

About the Speaker

You Might Also Like

Peripheral blood analysis is key to developing effective cancer immunotherapies

Five things to look for in an immune profiling partner

Flow vs. Spectral vs. Mass Cytometry: What’s the difference?